Abstract:Wilson's disease, first described by Samuel Wilson in 1912, is an autosomal recessive metabolic disorder resulting from mutations in the ATP7B gene. The disease develops as a consequence of copper accumulating in affected tissues. There is no gold standard for the diagnosis of Wilson's disease, which is often delayed due to the non‐specific clinical features and the need for a combination of clinical and laboratory tests for diagnosis. This delay may in turn affect clinical outcome and has implications for other family members in terms of diagnosis. The Leipzig criteria were established to help standardise diagnosis and management. However, it should be emphasised that these criteria date from 2003, and many of these have not been formally evaluated; this review examines the evidence behind biochemical testing for Wilson's disease. To determine the diagnostic accuracy of three biochemical tests at specified cut‐off levels for Wilson's disease. The index tests covered by this Cochrane Review are caeruloplasmin, 24‐hour urinary copper and hepatic copper content. These tests were evaluated in those with suspected Wilson's disease and appropriate controls (either healthy or those with chronic liver disease other than Wilson's). In the absence of a gold standard for diagnosing Wilson's disease, we have used the Leipzig criteria as a clinical reference standard. To investigate whether index tests should be performed in all individuals who have been recommended for testing for Wilson's disease, or whether these tests should be limited to subgroups of individuals. We identified studies by extensive searching of, e.g. the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, the Web of Science and clinical trial registries (29 May 2019). Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Inborn Errors of Metabolism Register: 29 May 2019. We included prospective and retrospective cohort studies that assessed the diagnostic accuracy of an index test using the Leipzig criteria as a clinical reference standard for the diagnosis of Wilson's disease. Two review authors independently reviewed and extracted data and assessed the methodological quality of each included study using the QUADAS‐2 tool. We had planned to undertake meta‐analyses of the sensitivity, specificity at relevant cut‐offs for each of the biochemical tests for Wilson's, however, due to differences in the methods used for each biochemical index test, it was not possible to combine the results in meta‐analyses and hence these are described narratively. Eight studies, involving 5699 participants (which included 1009 diagnosed with Wilson's disease) were eligible for inclusion in the review. Three studies involved children only, one adults only and the four remaining studies involved both children and adults. Two evaluated participants with hepatic signs and six with a combination of hepatic and neurological signs and symptoms of Wilson's disease, as well as pre‐symptomatic individuals. The studies were of variable methodological quality; with high risk if bias for participant selection and the reference standard used being of greatest methodological concern. Key differences between studies include differences in assay methodology, different cut‐off values for diagnostic thresholds, different age and ethnicity groups. Concerns around study design imply that diagnostic accuracy figures may not transfer to populations outside of the relevant study. Index test: caeruloplasmin Five studies evaluated various thresholds of caeruloplasmin (4281 participants, of which 541 had WD). For caeruloplasmin a cut‐off of 0.2 g/L as in the Leipzig criteria achieved a sensitivity of 77.1% to 99%, with variable specificity of 55.9% to 82.8%. Using the cut‐off of 0.1 g/L of the Leipzig criteria seemed to lower the sensitivity overall, 65% to 78.9%, while increasing the specificity to 96.6% to 100%. Index test: hepatic copper Four studies evaluated various thresholds of hepatic copper (1150 participants, of which 367 had WD). The hepatic copper cut‐off of 4 μmol/g used in the Leipzig criteria achieved a sensitivity of 65.7% to 94.4%, with a variable specificity of 52.2% to 98.6%. Index test: 24‐hour urinary copper Three studies evaluated various thresholds of 24‐hour urinary copper (268 participants, of which 101 had WD). For 24‐hour urinary copper, a cut‐off of 0.64 to 1.6 μmol/24 hours used in the Leipzig criteria achieved a variable sensitivity of 50.0% to 80.0%, with a specificity of 75.6% to 98.3%. The cut‐offs used for caeruloplasmin, 24‐hour urinary copper and hepatic copper for diagnosing Wilson's disease are method‐dependent and require validation in the population in which such index tests are going to be used. Binary cut‐offs and use of single‐test strategies to rule Wilson's disease in or out is not supported by the evidence in this review. There i -Abstract Truncated-

Urinary copper/zinc ratio: a promising parameter for replacement of 24-hour urinary copper excretion for diagnosis of Wilson’s disease in children

The Diagnostic Value of Morning Urine Copper to Zinc Ratio in Children with Wilson's Disease

Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?

The Reassessment of the Diagnostic Value of 24-Hour Urinary Copper Excretion in Children with Wilson's Disease

Population Screening and Diagnostic Strategies in Screening Family Members of Wilson’s Disease Patients

Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology

Relative exchangeable copper, a high-quality biomarker for differentiation of Traditional Chinese Medicine syndrome in Wilson's disease

Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets

Total Copper and Labile Bound Copper Fraction as a Selective and Sensitive Tool in the Evaluation of Wilson Disease

Analysis on the multi-metal element levels in morning urine of Wilson' s disease patients during penicillamine therapy

Zinc Mono-Therapy in Pre-Symptomatic Chinese Children with Wilson Disease: a Single Center, Retrospective Study.

Metal Element Excretion in 24-h Urine in Patients with Wilson Disease under Treatment of d -Penicillamine

Biomarkers for diagnosis of Wilson's disease.

Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson’s Disease

Accurate non-ceruloplasmin bound copper: a new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS

Diagnostic efficacy and influence factors of urinary protein/creatinine ratio replacing 24-h urine protein as an evaluator of proteinuria in children

Analysis of Multiple Elements in Urine of Patients with Wilson's Disease During Penicillamine Therapy

Exchangeable serum copper: Adult and pediatric reference intervals and in vitro stability in a nordic cohort

Biomedical copper speciation in relation to Wilson's disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry

A Single Determination of Liver Copper Concentration May Misdiagnose Wilson’s Disease

[Prognostic Value of Serum Trace Elements Copper and Zinc Levels in Sepsis Patients].